title: [Cost-effectiveness analysis: radioiodine or antithyroid medication in primary treatment of immune hyperthyroidism].
abstract: OBJECTIVE
  As first-line therapy of hyperthyroidism caused by Graves' disease antithyroid drugs are favoured in Europe, while radioiodine therapy is favoured in the USA. Radioiodine therapy has become more economic in Germany since the new recommendations by the Federal German Radiation Protection Committee (SSK) for patient discharge guidelines.
  
  
  METHODS
  Sensitivity analyses took into account the long-term relapse rate of conservative or radioiodine therapy, use of diagnostic tests, level of health insurance, drops in productivity and a discount factor. Costing models included the costs of follow-up care over 30 years. The costs of the hospitalisation for radioiodine therapy were calculated for 300 patients, discharged with 250 MBq 1-131 residual activity.
  
  
  RESULTS
  Antithyroid drugs were considered cost-effective when they achieved relapse rate of 50% or less, a cut in the number of tests needed and reduced working hours. Failure to meet any one of these conditions makes primary radioiodine therapy more cost-effective in 1593 of 1944 calculated costing models. Repeated conservative therapies will increase clearly the overall costs.
  
  
  CONCLUSIONS
  Radioiodine is a cost-effective, first-line therapy in patients with a special risk of relapse after primary conservative therapy (goitre, younger patient, persistent elevated TSH-receptor-antibodies or Tc-uptake).
authors.affiliation: Klinik und Poliklinik für Nuklearmedizin, Universität zu Köln, Deutschland.
authors.forename: M
authors.initials: M
authors.lastname: Dietlein
authors.forename: D
authors.initials: D
authors.lastname: Moka
authors.forename: B
authors.initials: B
authors.lastname: Dederichs
authors.forename: E
authors.initials: E
authors.lastname: Hunsche
authors.forename: K W
authors.initials: KW
authors.lastname: Lauterbach
authors.forename: H
authors.initials: H
authors.lastname: Schicha
mesh_terms: D013956:Antithyroid Agents / Q000191:economics / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis; D005858:Germany; D006111:Graves Disease / Q000188:drug therapy* / Q000191:economics / Q000532:radiotherapy*; D006801:Humans; D007457:Iodine Radioisotopes / Q000191:economics / Q000627:therapeutic use*